Reynold A. Panettieri, Jr, M.D.

Reynold A. Panettieri, Jr, M.D.

Vice Chancellor for Translational Medicine and Science Director, Rutgers Institute for Translational Medicine and Science Professor of Medicine, Robert Wood Johnson Medical School Emeritus Professor of Medicine, University of Pennsylvania


Rutgers Institute for Translational Medicine and Science
Child Health Institute of New Jersey
Rutgers, The State University of New Jersey
89 French Street
New Brunswick, NJ 08901

(732) 235-6404



M.D., University of Pennsylvania, Philadelphia, PA


Hospital of the University of Pennsylvania, Philadelphia, PA


Hospital of the University of Pennsylvania, Philadelphia, PA
Reynold A. Panettieri, Jr, MD, the inaugural Director of the Institute for Translational Medicine and Science and Vice Chancellor for Translational Medicine and Science at Rutgers University, previously served as the Director of the Airways Biology Initiative at the University of Pennsylvania. His interests include the cellular and molecular mechanisms that regulate airway smooth muscle cell growth and the immunobiology of airway smooth muscle. Consequences of increases in airway smooth muscle growth promote the development of irreversible airflow obstruction and airway remodeling seen in patients with chronic severe asthma. Dr. Panettieri’s lab also focuses on cytosolic signaling pathways that mediate gene expression and alter myocyte growth.

Dr. Panettieri also served as the Deputy Director of the Center of Excellence in Environmental Toxicology at the University of Pennsylvania. He directed the human exposure chamber that defines the molecular mechanisms regulating ozone- and particulate matter-induced airway hyperresponsiveness.
In addition to his research and clinical interests, Dr. Panettieri served as chairperson of the NIH Lung Cellular, Molecular, and Immunobiology Study Section, is a member of the NIH Distinguished Editorial Panel, and is a member of the American Society for Clinical Investigation and Association of American Physicians.

Current basic research projects open to fellow participation:

  • Immunobiology of airway smooth muscle: A major emphasis of our laboratory focuses on the immunobiology of airway smooth muscle (ASM) cells in asthma and chronic obstructive pulmonary disease (COPD). We have characterized that ASM can orchestrate and perpetuate airway inflammation through the secretion of chemokines/cytokines and expression of cell adhesion molecules. We define the critical signaling pathways by which structural cells modulate inflammatory responses, specifically the interplay of nuclear receptors such as vitamin D and glucocorticoids in inhibiting pro-inflammatory signals in mesenchymal cells.
  • Airway smooth muscle growth and airway remodeling: In some but not all patients with asthma, irreversible airflow obstruction occurs that evokes morbidity and mortality. A seminal finding of airway remodeling is increases in ASM mass. Our studies have recently defined that Regulators of G protein coupled Signaling (RGS) modulate ASM contractile responses and promote ASM cell growth. Our studies focus on novel approaches to inhibit ASM growth and maintain the contractile nature of human ASM cells. Specific tools utilize molecular approaches for cell signaling, as well as, novel imaging of cytosolic calcium and confocal bronchoscopy.
  • Environmental health studies and airway smooth muscle cell function: Ozone and other environmental toxins can induce airway hyperresponsiveness. The molecular mechanisms regulating ozone-mediated airway inflammation and airway hyperresponsiveness remain unclear. Our studies have defined novel eicosanoids and prostaglandins that mediate ozone-induced inflammation. Using translational biologic approaches in which a human exposure chamber delivers ozone to well-characterized patients with asthma and COPD, the characteristics of airway hyperresponsiveness and the molecular mechanisms regulating these phenotypes are defined.
  • Novel therapeutic approaches to treat airways diseases: Our laboratory has devoted considerable effort to collaborate with most major pharmaceutical companies to identify novel targets and platforms to test new therapeutic approaches in asthma and COPD. Using precision cut lung slices (PCLS) from humans and mice, the fundamental processes that regulate ASM contraction and growth can be defined, and novel therapeutics to inhibit such processes are characterized.

Selected publications

  1. Kammala AK, Bahal D, Yang C, Panettieri RA Jr, Das R, Subramanian H. Na+/H+ Exchanger Regulatory Factor 1 Mediates the Pathogenesis of Airway Inflammation in a Murine Model of House Dust Mite-Induced Asthma.J Immunol. 2021 May 15;206(10):2301-2311. doi: 10.4049/jimmunol.2001199. Epub 2021 May 5. PMID: 33952618.
  2. Dong YN, Hsu FC, Koziol-White CJ, Stepanova V, Jude J, Gritsiuta A, Rue R, Mott R, Coulter DA, Panettieri RA Jr, Krymskaya VP, Takano H, Goncharova EA, Goncharov DA, Cines DB, Lynch DR. Functional NMDA receptors are expressed by human pulmonary artery smooth muscle cells. Sci Rep. 2021 Apr 15;11(1):8205. doi: 10.1038/s41598-021-87667-0. PMID: 33859248.
  3. Mishra PK, Bruiners N, Ukey R, Datta P, Onyuka A, Handler D, Hussain S, Honnen W, Singh S, Guerrini V, Yin Y, Dewald H, Choudhary A, Horton DB, Barrett ES, Roy J, Weiss SH, Fitzgerald-Bocarsly P, Blaser MJ, Carson JL, Panettieri RA, Lardizabal A, Chang TL, Pinter A, Gennaro ML.Vaccination boosts protective responses and counters SARS-CoV-2-induced pathogenic memory B cells.  medRxiv. 2021 Apr 14:2021.04.11.21255153. doi: 10.1101/2021.04.11.21255153. Preprint. PMID: 33880486.
  4. Fuentes N, McCullough M, Panettieri RA Jr, Druey KM. RGS proteins, GRKs, and beta-arrestins modulate G protein-mediated signaling pathways in asthma. Pharmacol Ther. 2021 Feb 15;223:107818. Online ahead of print.
  5. Ghosh A, Koziol-White CJ, Jester WF Jr, Erzurum SC, Asosingh K, Panettieri RA Jr, Stuehr DJ. An inherent dysfunction in soluble guanylyl cyclase is present in the airway of severe asthmatics and is associated with aberrant redox enzyme expression and compromised NO-cGMP signaling. Redox Biol. 2021 Feb;39:101832. Epub 2020 Dec 13.
  6. Gebski EB, Anaspure O, Panettieri RA, Koziol-White CJ. Airway smooth muscle and airway hyperresponsiveness in asthma – mechanisms of airway smooth muscle dysfunction. Minerva Med. 2021 Jan 26. Online ahead of print.
  7. Barrett ES, Horton DB, Roy J, Xia W, Greenberg P, Andrews T, Gennaro ML, Parmar V, Russell WD, Reilly N, Uprety P, Gantner JJ, Stockman L, Trooskin SZ, Blaser MJ, Carson JL, Panettieri RA Jr. Risk Factors for Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Hospital Workers: Results From a Screening Study in New Jersey, United States in Spring 2020. Open Forum Infect Dis. 2020 Oct 31;7(12):ofaa534. eCollection 2020 Dec.
  8. Huang J, Lam H, Koziol-White C, Limjunyawong N, Kim D, Kim NKarmacharya N, Rajkumar P, Firer D, Dalesio NM, Jude J, Kurten RC, Pluznick JL, Deshpande DA, Penn RB, Liggett SB, Panettieri RA, Dong X, An SS. The odorant receptor OR2W3 on airway smooth muscle evokes bronchodilation via a cooperative chemosensory tradeoff between TMEM16A and CFTR. PNAS 2020 Oct 23. Online ahead of print.
  9. Panettieri RA Jr, Carson J, Horton D, Barrett E, Roy J, Radbel J. Asthma and COVID: What Are the Important Questions? J Allergy Clin Immunol Pract. 2020 Jun 22;S2213-2198(20)30606-1. Epub ahead of print.
  10. Radbel J, Jagpal S, Roy J, Brooks A, Tischfield J, Sheldon M, Bixby C, Witt D, Gennaro ML, Horton DB, Barrett ES, Carson JL, Panettieri RA Jr, Blaser MJ. Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Is Comparable in Clinical Samples Preserved in Saline or Viral Transport Medium. Version 2. J Mol Diagn. 2020 Jul;22(7):871-875. Epub 2020 May 13.
  11. Moore WC, Panettieri RA Jr, Trevor J, Ledford DK, Lugogo N, Soong W, Chipps BE, Carr W, Belton L, Gandhi H, Trudo F, Ambrose CS. Biologic and maintenance systemic corticosteroid therapy among US subspecialist-treated patients with severe asthma. Ann Allergy Asthma Immunol. 2020 Apr 15;S1081-1206(20)30232-5. Epub ahead of print.
  12. Omary MB, Eswaraka J, Kimball SD, Moghe PV, Panettieri RA Jr, Scotto KW. The COVID-19 pandemic and research shutdown: staying safe and productive. J Clin Invest. 2020 Jun 1;130(6):2745-2748.
  13. Wong GS, Redes JL, Balenga N, McCullough M, Fuentes N, Gokhale A, Koziol-White C, Jude JA, Madigan LA, Chan EC, Jester WH, Biardel S, Flamand N, Panettieri RA Jr, Druey KM. RGS4 promotes allergen- and aspirin-associated airway hyperresponsiveness by inhibiting PGE2 biosynthesis. J Allergy Clin Immunol. 2020 Mar 19;S0091-6749(20)30372-9. Epub ahead of print.
  14. Nuñez FJ, Johnstone TB, Corpuz ML, Kazarian AG, Mohajer NN, Tliba O, Panettieri RA Jr, Koziol-White C, Roosan MR, Ostrom RS. Glucocorticoids rapidly activate cAMP production via G<sub>αs</sub> to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects. FASEB J. 2020 Feb;34(2):2882-2895. Epub 2019 Dec 27.
  15. Koziol-White C, Johnstone TB, Corpuz ML, Cao G, Orfanos S, Parikh V, Deeney B, Tliba O, Ostrom RS, Dainty I, Panettieri RA Jr. Budesonide enhances agonist-induced bronchodilation in human small airways by increasing cAMP production in airway smooth muscle. Am J Physiol Lung Cell Mol Physiol. 2020 Feb 1;318(2):L345-L355. Epub 2019 Nov .